Search results
Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024...
The Pendulum· 4 days ago...Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, will present...at the 2024 ASCO Annual Meeting entitled "Phase 1 study of BAT8006, a folate receptor α antibody drug conjugate with strong...
Opinion: How to survive cancer with your heart and mind intact
Tulsa World· 5 days agoAt her first anniversary since being diagnosed with cancer, Meredith Poling writes about the advice...
Billionaire Groupon founder Eric Lefkofsky is back with another IPO: AI health tech Tempus
TechCrunch· 7 days agoEric Lefkofsky knows the public listing rodeo well and is about to enter it for a fourth time....
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 7 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
Stifel maintains $40 target on Celcuity, cites trial potential By Investing.com
Investing.com· 7 days agoThe firm's analyst highlighted the potential market opportunity for Celcuity's gedatolisib in...
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Zacks via Yahoo Finance· 2 days agoAffimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of...
Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival
Reuters· 6 days agoTrodelvy has accelerated U.S...Society of Clinical Oncology meeting in Chicago showed that Trodelvy...
Dublin biotech relocates HQ to Boston - Boston Business Journal
The Business Journals· 24 hours agoCarrick Therapeutics Inc. is shipping up to Boston. The clinical-stage cancer company has been based...
'Practice Changing' Trial for Inoperable Locally Advanced NSCLC
MedPage Today· 5 days agoEGFR testing now needed for all patients with stage III disease, experts say
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
Zacks via Yahoo Finance· 6 days agoGilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or...